Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de JNJ-69086420, un anticuerpo marcado con actinio-225 dirigido a la calicreína-2 humana (hK2) para el cáncer de próstata avanzado

2 de noviembre de 2026 actualizado por: Janssen Research & Development, LLC

Un estudio de fase 1 de JNJ-69086420, un anticuerpo marcado con actinio-225 dirigido a la calicreína-2 humana (hK2) para el cáncer de próstata avanzado

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion), to determine safety of JNJ-69086420 at the RP2D(s) as a combination therapy in Part 3 (combination therapy) and to determine safety of JNJ-69086420 at the RP2D(s) in participants with metastatic hormone-sensitive prostate cancer (mHSPC) in Part 4.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

144

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85054
        • Mayo Clinic Arizona
    • California
      • Duarte, California, Estados Unidos, 91010
        • City of Hope
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32224
        • Mayo Clinic in Florida
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago
    • Louisiana
      • Metairie, Louisiana, Estados Unidos, 70006
        • East Jefferson General Hospital
      • New Orleans, Louisiana, Estados Unidos, 70112
        • Tulane University Hospital & Clinics
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic Rochester
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68130
        • XCancer Omaha / Urology Cancer Center
    • New York
      • New York, New York, Estados Unidos, 10065
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • Case Western Reserve University
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • University of Utah Huntsman Cancer Institute

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Masculino

Descripción

Inclusion Criteria:

  • For Part 1, Part 2, Part 3: Metastatic castration resistant prostate cancer (mCRPC) with histologic confirmation of adenocarcinoma (adenocarcinoma with small-cell or neuroendocrine features is allowed) with prior exposure to at least one androgen receptor (AR) targeted therapy (for example [e.g.], abiraterone acetate, enzalutamide, apalutamide, darolutamide). In addition: Part 1: prior taxane or other chemotherapy is acceptable but not required. Part 2a: prior taxane or other chemotherapy required, Part 2b: no prior taxane or other chemotherapy, Part 2c: mCRPC that has progressed after prior treatment with lutetium Lu-177 vipivotide tetraxetan, with or without prior chemotherapy, Part 3: prior taxane or other chemotherapy is acceptable but not required & For Part 4a: metastatic HSPC, For Part 4b: disease that can be treated with less than or equal to (<=) 5 radiation fields and no visceral metastases
  • Parts 1, 2 & 3: Prior orchiectomy or medical castration, or, for participants who have not undergone orchiectomy, must be receiving ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analog (agonist or antagonist) prior to the first dose of study drug and must continue this therapy throughout the treatment phase. This criterion does not apply to Part 4
  • Palliative radiotherapy (e.g. soft tissue lesions) must be completed greater than (>) 2 weeks prior to start of study drug except for palliative radiotherapy for pain (e.g., bone pain), which may be used any time prior to first dose
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ functions as reflected in laboratory parameters

Exclusion Criteria:

  • Prior treatment with radium Xofigo (Ra 223 dichloride), strontium, samarium, or other radioconjugate therapy, other systemic anti-neoplastic therapy <=30 days prior to the first dose of study drug except for luteinizing hormone-releasing hormone agonists/antagonists or GnRH agonists/antagonists. Novel androgen axis drugs <=14 days prior to the first dose of study drug. In addition: Part 2b: Must not have received prior treatment with chemotherapy (eg, docetaxel) or poly ADP ribose polymerase (PARP) inhibitors, Part 2c: Prior treatment with lutetium Lu-177 vipivotide tetraxetan is required, but must have been completed >42 days prior to first dose of study drug, Part 3: Must not have received prior treatment with JNJ-78278343, Part 4: Must not have received ADT or AR-targeted therapy less than or equal to (<=) 56 days prior to first dose of study drug
  • Known history of myelodysplastic syndrome, leukemia, or hematological malignancy with features suggestive of myelodysplastic syndrome/acute myeloid leukemia at any timepoint
  • Toxicity from prior anticancer therapy has not resolved to baseline levels or to Grade <= 1 (except alopecia, radiation tissue fibrosis, or peripheral neuropathy)
  • Known allergies, hypersensitivity, or intolerance to JNJ-69086420 or its excipients and protein therapeutics. For Part 3, known allergies, hypersensitivity, or intolerance to JNJ-78278343 or its excipients or protein therapeutics
  • Active or chronic hepatitis B or hepatitis C infection

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part 1: Dose Escalation

Participants will receive JNJ-69086420 with one or multiple doses. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified.

Participants will receive JNJ-69086420.

Otros nombres:
  • Actinio-225-DOTA-h11B6
Experimental: Part 2: Dose Expansion

Participants in one or more cohorts will receive JNJ-69086420 at the RP2D(s) determined in Part 1.

Participants will receive JNJ-69086420.

Otros nombres:
  • Actinio-225-DOTA-h11B6
Experimental: Part 3: Combination Therapy

Participants will receive JNJ-69086420 at the determined RP2D(s) and fixed dose of JNJ-78278343.

Participants will receive JNJ-69086420.

Otros nombres:
  • Actinio-225-DOTA-h11B6

Participants will receive JNJ-78278343.

Experimental: Part 4: HSPC Expansion

Participants with HSPC will receive JNJ-69086420 at the RP2D(s) in Part 4(a), and JNJ-69086420 following stereotactic body radiation therapy in Part 4(b).

Participants will receive JNJ-69086420.

Otros nombres:
  • Actinio-225-DOTA-h11B6

Participants will receive stereotactic body radiaition therapy.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Periodo de tiempo: Up to 2 years and 4 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 2 years and 4 months
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
Periodo de tiempo: Up to 2 years and 4 months

Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Up to 2 years and 4 months
Number of Participants with AEs by Severity
Periodo de tiempo: Up to 2 years and 4 months

Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event.

Up to 2 years and 4 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Percentage of Participants with Prostate Specific Antigen (PSA) Response
Periodo de tiempo: Up to 2 years and 4 months

PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline and that is subsequently confirmed.

Up to 2 years and 4 months
Overall Response Rate (ORR)
Periodo de tiempo: Up to 2 years and 4 months

ORR is defined as the percentage of participants who have a Partial Response (PR) or better according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 without evidence of bone progression according to Prostate Cancer Working Group 3 (PCWG3).

Up to 2 years and 4 months
Maximum Observed Serum Concentration/Radioactivity (Cmax) of JNJ-69086420
Periodo de tiempo: Up to 2 years and 4 months

Cmax is defined as the maximum observed serum concentration/radioactivity of JNJ-69086420.

Up to 2 years and 4 months
Time to Reach Maximum Observed Serum Concentration/Radioactivity (Tmax) of JNJ-69086420
Periodo de tiempo: Up to 2 years and 4 months

Tmax is defined as time to reach maximum observed serum concentration/radioactivity of JNJ-69086420.

Up to 2 years and 4 months
Area Under the Serum Concentration-time Curve From Time Zero to t Time (AUC[0-t]) of JNJ-69086420
Periodo de tiempo: Up to 2 years and 4 months

AUC(0-t) is defined as the area under the serum concentration-time curve from time zero to t of JNJ-69086420.

Up to 2 years and 4 months
Number of Participants With Anti-JNJ-69086420 Antibodies
Periodo de tiempo: Up to 2 years and 4 months

Number of participants with anti-JNJ-69086420 antibodies will be assessed to evaluate the potential immunogenicity.

Up to 2 years and 4 months
Part 3: Serum Concentration of JNJ-78278343
Periodo de tiempo: Up to 2 years and 4 months

Venous blood samples will be collected for assessment of serum concentrations of JNJ-78278343.

Up to 2 years and 4 months
Part 3:Number of Participants With Anti-JNJ-78278343 Antibodies
Periodo de tiempo: Up to 2 years and 4 months

Number of participants with anti-JNJ-78278343 antibodies will be assessed to evaluate the potential immunogenicity.

Up to 2 years and 4 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

12 de noviembre de 2020

Finalización primaria (Estimado)

8 de diciembre de 2026

Finalización del estudio (Estimado)

30 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

20 de noviembre de 2020

Primero enviado que cumplió con los criterios de control de calidad

20 de noviembre de 2020

Publicado por primera vez (Actual)

25 de noviembre de 2020

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CR108817
  • 69086420PCR1001 (Otro identificador: Janssen Research & Development, LLC)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .